SCHEMBL534809

SCHEMBL534809

NCCC[C@@H](N)C(=O)OC(=O)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP7 Q9UHL4 2/20 0.48
TDP1 Q9NUW8 3/20 0.46
MMP2 P08253 1/20 0.44
ALDH1A1 P00352 2/20 0.44
SLC1A5 Q15758 1/20 0.43
DPP8 Q6V1X1 1/20 0.41
DPP9 Q86TI2 1/20 0.41
KMT2A Q03164 2/20 0.41
MAPK1 P28482 1/20 0.41
HIF1A Q16665 1/20 0.41
SLC6A2 P23975 1/20 0.41
SLC6A3 Q01959 1/20 0.41
GSR P00390 1/20 0.41
HTR2A P28223 1/20 0.41
HRH1 P35367 1/20 0.41
LMNA P02545 2/20 0.40
F2 P00734 1/20 0.40
LTA4H P09960 1/20 0.40
KDM4E B2RXH2 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzamide SCHEMBL28961117 0.89 DPP7 (0.48) DPP7TDP1MMP2ALDH1A1SLC1A5
SCHEMBL27792687 0.88 SLC1A5 (0.50) DPP7TDP1ALDH1A1SLC1A5KMT2A
SCHEMBL14343635 0.87 GSR (0.47) DPP7MMP2SLC1A5DPP8DPP9
SCHEMBL186936 0.86 LMNA (0.50) TDP1ALDH1A1SLC1A5MAPK1LMNA
SCHEMBL11403740 0.86 LMNA (0.50) TDP1ALDH1A1SLC1A5MAPK1LMNA
SCHEMBL14343323 0.85 DPP7 (0.44) DPP7MMP2DPP8DPP9GSR
SCHEMBL17821459 0.84 LMNA (0.47) TDP1ALDH1A1KMT2ALMNAKDM4E
Hydrochloric Acid SCHEMBL6751555 0.83 SLC1A5 (0.51) TDP1ALDH1A1SLC1A5KMT2AMAPK1
SCHEMBL1997086 0.83 ALDH1A1 (0.45) TDP1ALDH1A1SLC1A5KMT2AMAPK1
Benzamide SCHEMBL28629377 0.82 DPP7 (0.45) DPP7TDP1MMP2ALDH1A1DPP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250221954-A1 METHODS TO TREAT, PREVENT, OR REDUCE HYPERAMMONEMIA RUBIN DARREN ALEXANDER (US) 2025-07-10 US claimed
EP-2625162-B1 METHODS OF MAKING L-ORNITHINE PHENYL ACETATE OCERA THERAPEUTICS INC (US) 2019-03-13 EP claimed
US-9260379-B2 Methods of making L-ornithine phenyl acetate OCERA THERAPEUTICS, INC. (US) 2016-02-16 US claimed
US-20150133684-A1 METHODS OF MAKING L-ORNITHINE PHENYL ACETATE MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY 2015-05-14 US claimed
US-8946473-B2 Methods of making L-ornithine phenyl acetate OCERA THERAPEUTICS, INC. (US) 2015-02-03 US claimed
US-20130211135-A1 METHODS OF MAKING L-ORNITHINE PHENYL ACETATE OCERA THERAPEUTICS, INC. (US) 2013-08-15 US claimed
EP-2625162-A1 METHODS OF MAKING L-ORNITHINE PHENYL ACETATE Ocera Therapeutics Inc. (US) 2013-08-14 EP claimed
WO-2012048043-A1 METHODS OF MAKING L-ORNITHINE PHENYL ACETATE OCERA THERAPEUTICS, INC. (US) 2012-04-12 WO claimed
US-12516015-B2 L-ornithine phenyl acetate and methods of making thereof AMALIVE LIMITED (GB) 2026-01-06 US disclosed
US-20250221954-A1 METHODS TO TREAT, PREVENT, OR REDUCE HYPERAMMONEMIA RUBIN DARREN ALEXANDER (US) 2025-07-10 US disclosed
EP-4101838-A1 L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF Ocera Therapeutics, Inc. (US) 2022-12-14 EP disclosed
EP-3686183-B1 L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF OCERA THERAPEUTICS INC (US) 2022-08-03 EP disclosed
US-20220162155-A1 L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF VTESSE LLC 2022-05-26 US disclosed
US-11161802-B2 L-ornithine phenyl acetate and methods of making thereof OCERA THERAPEUTICS, INC. (US) 2021-11-02 US disclosed
US-8173706-B2 L-ornithine phenyl acetate and methods of making thereof OCERA THERAPEUTICS, INC. (US) 2012-05-08 US disclosed
CN-102421432-A L-ornithine phenylacetate and preparation method thereof OCERA THERAPEUTICS INC 2012-04-18 CN disclosed
WO-2012048043-A1 METHODS OF MAKING L-ORNITHINE PHENYL ACETATE OCERA THERAPEUTICS, INC. (US) 2012-04-12 WO disclosed
EP-2413924-A1 L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF Ocera Therapeutics, INC. (US) 2012-02-08 EP disclosed
US-20100280119-A1 L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF OCERA THERAPEUTICS, INC. (US) 2010-11-04 US disclosed
WO-2010115055-A1 L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF OCERA THERAPEUTICS, INC. (US) 2010-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150133684-A1 METHODS OF MAKING L-ORNITHINE PHENYL ACETATE OTC, OAT, ODC1 DPP7 567/4885TDP1 488/4885MMP2 2918/4885
US-20220162155-A1 L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF OAT, OTC, ODC1 DPP7 1895/4885TDP1 657/4885MMP2 2821/4885
US-20130211135-A1 METHODS OF MAKING L-ORNITHINE PHENYL ACETATE OTC, OAT, ODC1 DPP7 386/4885TDP1 541/4885MMP2 3194/4885
US-11161802-B2 L-ornithine phenyl acetate and methods of making thereof OAT, OTC, ODC1 DPP7 1895/4885TDP1 657/4885MMP2 2821/4885
US-20100280119-A1 L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF OAT, OTC, PYGL DPP7 1774/4885TDP1 686/4885MMP2 2909/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.